SEPTERNA, INC. COMMON STOCK
NASDAQ: SEPN (Septerna, Inc.)
Kemas kini terakhir: 1 jam lalu38.91
-1.56 (-3.85%)
| Penutupan Terdahulu | 40.47 |
| Jumlah Dagangan | 385,854 |
| Harga / Jualan (P/S) | 18.27 |
| Harga / Buku (P/B) | 4.88 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -11,831.05% |
| EPS Cair (TTM) | -1.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.25% |
| Nisbah Semasa (MRQ) | 32.19 |
| Aliran Tunai Operasi (OCF TTM) | -74.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.69 M |
| Pulangan Atas Aset (ROA TTM) | -17.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Septerna, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.64% |
| % Dimiliki oleh Institusi | 105.46% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |